7 stories mentioning SHA:600079Updated just now
Every FINWIRES story that references SHA:600079, newest first.
China's drug regulator approved clinical trials by Humanwell Healthcare (SHA:600079) subsidiary Yichang Humanwell for the tapentadol hydrochloride oral solution.The drug is a pain reliever for children aged 2 years and older and for adults weighing more than 16 kilograms, according to a Tuesday filing with the Shanghai bourse.
China's drug regulator approved Humanwell Healthcare (SHA:600079) subsidiary Wuhan Humanwell Pharmaceutical's drug registration for its hydrocortisone sodium succinate injection.The injection is indicated for patients with toxic infections, anaphylactic shock, severe adrenocortical conditions, severe bronchial asthma and prevention of acute graft rejection, according to a Tuesday filing with the Shanghai bourse.
Humanwell Healthcare (SHA:600079) subsidiary RFSW Holding will divest 81.7 million shares in Lefusi Health Industry and list them in a property exchange for 1.06 billion yuan.The shares are equivalent to a 16.34% equity in the nursing facility services company, according to a Friday filing with the Shanghai bourse.
China's National Medical Products Administration accepted the marketing application of Humanwell Healthcare's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, for landiolol hydrochloride for injection, according to a Shanghai bourse filing on Thursday.The drug is used for the treatment of tachyarrhythmias in patients with heart failure or during surgery.The pharmaceutical company invested 9.5 million yuan into the research and development of the drug.
Humanwell Healthcare (SHA:600079) unit has secured U.S. Food and Drug Administration approval for its generic version of the fertility drug cetrorelix acetate injection.The injection is a fertility treatment used to prevent premature luteinizing hormone surges in women undergoing controlled ovarian stimulation, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company declined 1% in recent trade.
Humanwell Healthcare (SHA:600079) unit obtained China's regulatory approval to begin clinical trials for RFUS-188 to treat acute pain, according to a Thursday filing with the Shanghai bourse.The drug targets peripheral kappa opioid receptors without crossing the blood-brain barrier, potentially eliminating the addiction, respiratory depression and other severe side effects of traditional opioidsShares of the pharmaceutical company declined 1% in recent trade.
Humanwell Healthcare (SHA:600079) attributable profit rose 8.9% to 588.2 million yuan in the first quarter from 540.3 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.Earnings per share at the drug company increased 9.1% to 0.36 yuan from 0.33 yuan in the prior-year period.Operating revenue slipped year over year to 6.10 billion yuan from 6.14 billion yuan.
